Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Missouri Baptist Medical Center
mi
from
Saint Louis, MO
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Missouri Baptist Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
CHI Health Saint Francis
mi
from
Grand Island, NE
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
CHI Health Saint Francis
mi
from
Grand Island, NE
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Heartland Hematology and Oncology
mi
from
Kearney, NE
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Heartland Hematology and Oncology
mi
from
Kearney, NE
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
CHI Health Good Samaritan
mi
from
Kearney, NE
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
CHI Health Good Samaritan
mi
from
Kearney, NE
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Elizabeth Regional Medical Center
mi
from
Lincoln, NE
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Elizabeth Regional Medical Center
mi
from
Lincoln, NE
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Alegent Health Immanuel Medical Center
mi
from
Omaha, NE
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Alegent Health Immanuel Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Alegent Health Bergan Mercy Medical Center
mi
from
Omaha, NE
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Alegent Health Bergan Mercy Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Alegent Health Lakeside Hospital
mi
from
Omaha, NE
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Alegent Health Lakeside Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Creighton University Medical Center
mi
from
Omaha, NE
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Creighton University Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Midlands Community Hospital
mi
from
Papillion, NE
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Midlands Community Hospital
mi
from
Papillion, NE
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Glens Falls Hospital
mi
from
Glens Falls, NY
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Glens Falls Hospital
mi
from
Glens Falls, NY
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
East Carolina University
mi
from
Greenville, NC
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
East Carolina University
mi
from
Greenville, NC
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Dayton Physicians LLC-Miami Valley South
mi
from
Centerville, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Dayton Physicians LLC-Miami Valley South
mi
from
Centerville, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Hospital - Cincinnati
mi
from
Cincinnati, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Hospital - Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Bethesda North Hospital
mi
from
Cincinnati, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Bethesda North Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
TriHealth Cancer Institute-Westside
mi
from
Cincinnati, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
TriHealth Cancer Institute-Westside
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
TriHealth Cancer Institute-Anderson
mi
from
Cincinnati, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
TriHealth Cancer Institute-Anderson
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Armes Family Cancer Center
mi
from
Findlay, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Armes Family Cancer Center
mi
from
Findlay, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Orion Cancer Care
mi
from
Findlay, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Orion Cancer Care
mi
from
Findlay, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Dayton Physicians LLC-Atrium
mi
from
Franklin, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Dayton Physicians LLC-Atrium
mi
from
Franklin, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Dayton Physicians LLC-Wayne
mi
from
Greenville, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Dayton Physicians LLC-Wayne
mi
from
Greenville, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Greater Dayton Cancer Center
mi
from
Kettering, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Greater Dayton Cancer Center
mi
from
Kettering, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Dayton Physicians LLC-Signal Point
mi
from
Middletown, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Dayton Physicians LLC-Signal Point
mi
from
Middletown, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Dayton Physicians LLC-Wilson
mi
from
Sidney, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Dayton Physicians LLC-Wilson
mi
from
Sidney, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Dayton Physicians LLC-Upper Valley
mi
from
Troy, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Dayton Physicians LLC-Upper Valley
mi
from
Troy, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
University Pointe
mi
from
West Chester, OH
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
University Pointe
mi
from
West Chester, OH
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Center-Cancer Center Hazleton
mi
from
Hazleton, PA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Center-Cancer Center Hazleton
mi
from
Hazleton, PA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Oncology-Lewisburg
mi
from
Lewisburg, PA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Oncology-Lewisburg
mi
from
Lewisburg, PA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Lewistown Hospital
mi
from
Lewistown, PA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Lewistown Hospital
mi
from
Lewistown, PA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Geisinger Wyoming Valley/Henry Cancer Center
mi
from
Wilkes-Barre, PA
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Geisinger Wyoming Valley/Henry Cancer Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Memorial Hospital
mi
from
Chattanooga, TN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Memorial Hospital
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Pulmonary Medicine Center of Chattanooga-Hixson
mi
from
Hixson, TN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Pulmonary Medicine Center of Chattanooga-Hixson
mi
from
Hixson, TN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Memorial GYN Plus
mi
from
Ooltewah, TN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Memorial GYN Plus
mi
from
Ooltewah, TN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Memorial Hermann Texas Medical Center
mi
from
Houston, TX
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Memorial Hermann Texas Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
South Jordan Health Center
mi
from
South Jordan, UT
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
South Jordan Health Center
mi
from
South Jordan, UT
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
University of Vermont Medical Center
mi
from
Burlington, VT
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
University of Vermont Medical Center
mi
from
Burlington, VT
Click here to add this to my saved trials